Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesOver-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner
Gynecologic Oncology, 08/23/06
Xiaojuan Yan, et al. - Resistance to cisplatin-centered chemotherapy is a major cause of treatment failure in human ovarian cancer...Conclusion: Taken together, these data suggest that PTEN over-expression may represent a novel therapeutic approach for chemoresistant human ovarian cancer and that this may involve a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway
| Previous Article | Next Article |
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Expression of ER-α36, a novel variant of estrogen receptor-α, and resistance to tamoxifen treatment in breast cancer
Journal of Clinical Oncology, 06/04/09
Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia
Medical Oncology, 06/05/09
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor-alpha; therapy: Is there a need for more comprehensive screening procedures?
Arthritis Care and Research , 06/03/09
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Age-appropriate use of human papillomavirus vaccines in the US
Gynecologic Oncology, 06/30/09
Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
European Journal of Cancer, 06/15/09
Update: Endometrial Cancer
OBG Management, 07/02/09
Sponsor
Article Search
Sponsor